Beyond the Visible Lesion: SmartLux and Red-Light PDT

For skin cancer clinics treating patients with years of sun exposure, the visible lesions are often only part of the problem. A patient may present with several actinic keratoses (AKs) on the forehead or scalp, while the surrounding skin shows signs of more extensive UV damage. 

Treating individual lesions is important, but it doesn’t necessarily address the damaged skin around them. Photodynamic therapy (PDT) offers another approach, allowing clinicians to treat a broader area rather than concentrating solely on what can be seen. 

PDT combines a topical photosensitising agent with light of an appropriate wavelength to produce a reaction that damages targeted cells. SmartLux, with its 635 nm red-light capability, provides controlled illumination relevant to conventional red-light PDT protocols. 

Treating the field, not just the lesion

Actinic keratoses frequently develop within broader areas of sun-damaged skin, known as field cancerisation. Although individual lesions may be clearly visible, the surrounding skin can contain subclinical cellular changes that are not yet apparent on examination. 

In a 2025 review published in Cancers, Sotiriou and colleagues examined the role of PDT in managing AKs and field cancerisation. The authors identified PDT as an effective treatment for non-hyperkeratotic AKs, with the additional benefit of addressing surrounding sun-damaged skin. 

This makes field-directed treatment particularly relevant for patients with multiple lesions or widespread photodamage on areas such as the scalp, forehead, temples and face.  

It is not, however, appropriate for every AK. Lesion thickness, location and individual patient factors still need to be considered when deciding on treatment. 

 

The science behind PDT 

PDT relies on three components: 

  • A photosensitising agent 

  • Light of an appropriate wavelength 

  • Molecular oxygen within the tissue 

Treatment begins with the application of a topical photosensitising precursor, usually 5-aminolevulinic acid (ALA) or methyl aminolevulinate (MAL). 

Once absorbed, these compounds are converted into photosensitive porphyrins, predominantly protoporphyrin IX (PpIX), which accumulate within the target tissue. 

When PpIX absorbs light at an appropriate wavelength, it enters an excited state. The resulting interaction with molecular oxygen produces reactive oxygen species (ROS), which cause oxidative cellular damage.

This photochemical reaction is responsible for PDT’s therapeutic effect. Unlike conventional LED therapy, red-light exposure alone does not produce the same cytotoxic response. The photosensitiser must be present and activated for the photodynamic reaction to occur. 

 

Why red light? 

The wavelength used in PDT is determined by how the photosensitiser responds to light. 

PpIX absorbs light across several regions of the visible spectrum, including a clinically useful absorption band in the red region. Red light also penetrates tissue more deeply than shorter visible wavelengths, helping explain its established use in dermatological PDT. 

SmartLux delivers red light at 635 nm, a wavelength relevant to conventional red-light PDT protocols. 

But wavelength alone doesn’t determine effectiveness. Irradiance, total fluence or light dose, exposure duration, treatment distance, photosensitiser selection, incubation time and lesion characteristics all influence the treatment. 

A device’s ability to emit 635 nm light does not, by itself, establish that it can reproduce the results of a particular clinical PDT protocol. 

 

What the clinical research shows 

In a 2018 randomised, intra-individual study, Sotiriou and colleagues assessed conventional lamp-based PDT in patients with facial and scalp AKs. 

At three months, complete lesion response with conventional PDT was 80.6%. At 12 months, the response rate was 73.7%. 

These results show a high initial response that was largely maintained at 12-month follow-up. 

 

Why controlled illumination matters 

A 2023 study by Ruiz and colleagues, published in Skin Health and Disease, included a conventional lamp-based PDT protocol using ALA. 

The lamp protocol involved a 30-minute ALA pre-incubation followed by ten minutes of red-light exposure. The study illustrates how artificial illumination can be incorporated into a defined clinical protocol, with specific parameters for photosensitiser incubation and light exposure. 

Lamp-based illumination allows clinicians to control the conditions under which light is delivered, helping keep treatment parameters consistent from session to session and appointments predictable. 

 

How SmartLux works with PDT 

SmartLux provides a high-intensity 635 nm red-light platform capable of delivering controlled illumination. Within an appropriately designed PDT protocol, the treatment involves five stages: 

  • Apply the photosensitiser. A topical photosensitising precursor is applied to the treatment area. 

  • Allow PpIX to accumulate. A defined incubation period gives the photosensitising process time to occur. 

  • Deliver 635 nm red light. SmartLux provides the light energy required for photoactivation, subject to appropriate treatment settings. 

  • Activate the PpIX. The excited photosensitiser interacts with molecular oxygen in the tissue. 

  • Generate reactive oxygen species. The resulting oxidative reaction damages targeted cells. 

More than a single-purpose light platform 

SmartLux also offers multiple wavelengths, allowing clinics to consider other phototherapy applications beyond PDT. PDT should not, however, be confused with photobiomodulation (PBM). 

PDT activates a photosensitising agent to produce a cytotoxic photochemical reaction in targeted tissue. Photobiomodulation uses light without an externally applied photosensitiser to influence cellular processes. 

Although both involve light-based technology, their biological mechanisms and clinical objectives are different. Understanding that distinction helps clinicians select appropriate treatments and explain them accurately to patients. 

 

Bringing PDT into the skin cancer clinic 

For appropriately selected patients, PDT offers an established treatment option for actinic keratoses across areas of chronic sun damage.  SmartLux provides a platform that may be considered as part of a clinician-directed PDT workflow, subject to appropriate treatment parameters and device indications. 

The choice of light source is important, but successful treatment also depends on selecting the appropriate photosensitiser, light settings and clinical protocol.

 

Selected published evidence 

1.Sotiriou E, et al. (2025). Daylight Photodynamic Therapy for Actinic Keratosis and Field Cancerization: A Narrative Review. Cancers, 17(6):1050. The review discusses the role of PDT in treating AKs and surrounding field cancerisation. 

View published paper [mdpi.com] 

2.Sotiriou E, et al. (2018). Conventional vs. daylight photodynamic therapy for patients with actinic keratosis on face and scalp: 12-month follow-up results of a randomized, intra-individual comparative analysis. Journal of the European Academy of Dermatology and Venereology, 32(4):595–600. Complete lesion response at three months was 80.6% with conventional PDT. 

View on PubMed [pubmed.ncb...lm.nih.gov] 

3.Ruiz AJ, et al. (2023). Equivalent efficacy of indoor daylight and lamp-based 5-aminolevulinic acid photodynamic therapy for treatment of actinic keratosis. Skin Health and Disease, 3(4):e226. This study included a conventional red-light lamp PDT protocol using ALA. 

View published paper [pmc.ncbi.nlm.nih.gov] 

← Older Post